Immunome, Inc. $IMNM Shares Acquired by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. increased its stake in Immunome, Inc. by 43.4%, acquiring an additional 1,303,753 shares, bringing its total ownership to approximately 4.95% of the company, valued at nearly $29 million.
• Immunome received positive ratings from several analysts, with price targets set between $18.00 and $25.00, indicating a generally optimistic outlook on the company's stock.
• Despite reporting negative earnings per share of ($0.50) for the quarter, Immunome exceeded revenue expectations with $4.02 million, significantly higher than the forecasted $1.03 million.

Vanguard Group Inc. lifted its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 43.4% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 4,307,191 shares of the company's stock after purchasing an additional 1,303,753 shares during the period. Vanguard Group Inc. owned about 4.95% of Immunome worth $28,987,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of IMNM. Wells Fargo & Company MN lifted its position in shares of Immunome by 45.5% in the 4th quarter. Wells Fargo & Company MN now owns 26,207 shares of the company's stock worth $278,000 after purchasing an additional 8,190 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Immunome in the 4th quarter worth approximately $274,000. MetLife Investment Management LLC lifted its position in shares of Immunome by 17.7% in the 4th quarter. MetLife Investment Management LLC now owns 35,619 shares of the company's stock worth $378,000 after purchasing an additional 5,354 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after purchasing an additional 7,129 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Immunome by 12.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,282,754 shares of the company's stock worth $24,243,000 after purchasing an additional 246,447 shares during the period. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Price Performance

IMNM traded down $0.23 on Tuesday, reaching $9.28. 568,776 shares of the company's stock were exchanged, compared to its average volume of 627,134. The stock has a market cap of $807.73 million, a PE ratio of -3.01 and a beta of 1.92. The stock's fifty day moving average price is $9.80 and its 200-day moving average price is $8.84. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $16.73.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.02. The company had revenue of $4.02 million for the quarter, compared to analyst estimates of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. As a group, research analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IMNM has been the subject of a number of analyst reports. Wedbush reissued an "outperform" rating and set a $21.00 target price on shares of Immunome in a research report on Thursday, August 7th. Evercore ISI began coverage on shares of Immunome in a research report on Friday, August 22nd. They set an "outperform" rating and a $18.00 target price for the company. JPMorgan Chase & Co. decreased their price target on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Guggenheim reaffirmed a "buy" rating and issued a $25.00 price target on shares of Immunome in a report on Monday, August 25th. Finally, Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $22.50.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.